ERBB2 and neoplasm: In previous proof-of-concept analyses, we demonstrated the enhanced and CAR-specific cytotoxicity of NK-92/5.28.z cells compared to parental NK-92 cells against 2D ErbB2-positive RMS tumor cell lines (19).